Method for long-term treatment of rosacea

Abstract

A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.

What is claimed is: 
     
         1 . A regimen for the long-term therapeutic treatment of rosacea, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of up to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%, wherein the success rate is defined as a percentage of the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition. 
     
     
         2 . The regimen of  claim 1 , wherein the benzoyl peroxide is the sole active ingredient administered to the subject during the duration of the regimen. 
     
     
         3 . The regimen of  claim 1 , wherein the pharmaceutical composition comprises about 2.5% w/w to about 10% w/w of benzoyl peroxide. 
     
     
         4 . The regimen of  claim 3 , wherein the pharmaceutical composition comprises about 5% w/w of benzoyl peroxide. 
     
     
         5 . The regimen of  claim 1 , wherein the benzoyl peroxide is selected from a solid, solution or suspension form. 
     
     
         6 . The regimen of  claim 1 , wherein the regimen is a first line therapy for the treatment of rosacea. 
     
     
         7 . The regimen of  claim 1 , wherein the rosacea is any of erythematotelengietatic rosacea, papulopustular rosacea, phymatous rosacea or ocular rosacea. 
     
     
         8 . The regimen of  claim 1 , wherein said pharmaceutical composition is a cream or an emulsion. 
     
     
         9 . The regimen of  claim 1 , wherein said pharmaceutical composition is an extended release formulation. 
     
     
         10 . The regimen of  claim 9 , wherein the extended-release effect is obtained by encapsulation, microencapsulation, microspheres or coating. 
     
     
         11 . The regimen of  claim 10 , wherein the benzoyl peroxide is encapsulated or microencapsulated. 
     
     
         12 . The regimen of  claim 10 , wherein the benzoyl peroxide is included in a microsphere or a coating. 
     
     
         13 . The regimen of  claim 1 , wherein the rosacea is moderate to severe rosacea. 
     
     
         14 . The regimen of  claim 1 , wherein a percentage of subjects having no adverse effects after treatment with the pharmaceutical composition after about 52 weeks is at least 75%. 
     
     
         15 . The regimen of  claim 14 , where the percentage of subjects having no adverse effects after treatment with the pharmaceutical composition after about 52 weeks is from about 75% to about 85%. 
     
     
         16 . The regimen of  claim 1 , wherein the adverse effect is selected from itching, burning, dryness, itching and a combination thereof.